Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-213 manufacturers

Filters

Filters

Filters , active

Country of origin : China
None products found

pp-213

Solution for injection

Dossier type
US CTD
Dossier status
Under development
Country of origin
China
GMP approvals
FDA
Comments
Indication: Paroxysmal nocturnal haemoglobinuria (PNH) and IgA nephropathy (IgAN) Clinical stage: Phase 2 — first patients dosed April 2026 (Phase 2 for PNH/IgAN) Modality: Biological (GalNAc-conjugated siRNA targeting complement factor B — NBE) Mechanism / Target: First-in-class siRNA silencing complement factor B (CFB), rate-limiting enzyme of the alternative complement pathway convertase; monthly SC dosing via GalNAc conjugation; reduces alternative-pathway-driven haemolysis (PNH) and IgA-immune-complex deposition (IgAN) Route / form: Subcutaneous injection (monthly) Differentiation: First CFB-targeting siRNA for complement-mediated haematological/renal disease; addresses PNH patients with extravascular haemolysis not covered by eculizumab/ravulizumab; Phase 2 first patients April 2026;
Manufacturer #39350

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.